State Street Corp Humanigen, Inc Transaction History

State Street Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.09 - $0.2 $2,412 - $5,360	-26,800 Reduced 12.44%	188,676 $22,000
Q3 2022 Nov 15, 2022	SELL	$0.15 - $3.02 $24,930 - $501,924	-166,200 Reduced 43.54%	215,476 $39,000
Q2 2022 Aug 15, 2022	SELL	$1.76 - $3.33 $1.52 Million - $2.88 Million	-865,246 Reduced 69.39%	381,676 $676,000
Q1 2022 May 16, 2022	BUY	$1.81 - $3.97 $543,624 - $1.19 Million	300,345 Added 31.73%	1,246,922 $3.75 Million
Q4 2021 Feb 14, 2022	SELL	$3.66 - $8.22 $28.7 Million - $64.6 Million	-7,854,914 Reduced 89.25%	946,577 $3.52 Million
Q3 2021 Nov 15, 2021	BUY	$5.93 - $17.83 $34.6 Million - $104 Million	5,829,894 Added 196.19%	8,801,491 $52.2 Million
Q2 2021 Aug 16, 2021	SELL	$13.54 - $22.74 $1.61 Million - $2.71 Million	-119,140 Reduced 3.85%	2,971,597 $51.6 Million
Q1 2021 May 17, 2021	BUY	$12.91 - $23.83 $39.5 Million - $73 Million	3,063,237 Added 11139.04%	3,090,737 $59 Million
Q4 2020 Feb 16, 2021	BUY	$7.97 - $21.66 $219,175 - $595,650	27,500 New	27,500 $481,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.